<DOC>
	<DOCNO>NCT01863511</DOCNO>
	<brief_summary>For patient hospitalize acute decompensated heart failure , volume removal remain primary therapeutic objective . The current standard care remain loop diuretics.The high likelihood readmission poor outcome highlight need examine improve in-hospital protocol patient . Ultrafiltration allow great volume removal , less neurohormonal stimulation great sodium removal.However associate increased cost , line complication , relative immobility treatment . Tolvaptan addition diuretic therapy show improve amount volume remove compare diuretic alone . The study propose compare strategy add tolvaptan usual care ultrafiltration primary mode therapy acute decompensated HF ( ADHF ) patient . Hypothesis : addition tolvaptan usual care hospitalize HF patient result : - great volume weight reduction compare usual care - similar efficacy outcome compare ultrafiltration , less complication therapy</brief_summary>
	<brief_title>Tolvaptan/Ultrafiltration Treatment Acute Heart Failure</brief_title>
	<detailed_description>Study design prospective randomize open label unblinded comparison two different approach volume removal . Enrolled patient evaluate target weight remove . Patients randomize usual care ( UC ) , usual care plus tolvaptan ( UC+T ) ultrafiltration ( UF ) , within 12 hour presentation . Treatment UC UC+T arm begin furosemide bolus ( double home dose unavailable , 60mg ) continue drip ( 10 20 mg/hr ) . In addition UC+T group treat tolvaptan 30 mg orally daily . Patients UF arm treat UF administer brachial line catheter internal jugular vein . Loop thiazide diuretic discontinue , although aldosterole antagonist continue . Urinary neutrophil gelatinase associate lipocalcin ( uNGAL ) level elevate renal dysfunction may sensitive biomarker distinguish intrinsic renal damage reversible , transient prerenal azotemia.Characterizing change uNGAL level course ADHF therapy , comparison patient weight , BUN creatinine level important step establish role potential promise biomarker ADHF treatment strategy . Protocol highlight patient include : Baseline labs daily day 4 discharge ( BMP , BNP , CBC , urine creatinine sodium , uNGAL ) - Daily weight - Daily volume status : total intake , urine output , ultrafiltrate volume - Collect urine ultrafiltrate 24 hour collection bag , record volume , creatinine Na level - length stay - hospital day 4 : Minnesota Living Heart Failure questionnaire - Cost hospitalization</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>2 3 physical exam finding volume overload ( rale , JVP 5 cm edema ) BNP 300 contraindication ultrafiltration ( line insertion , heparin use ) serum creatinine &gt; 3mg/dL Na &gt; 145 inotrope vasopressor dependency active infection , include urinary tract resynchronization therapy coronary intervention past 30 day life expectancy le 6 month hypertrophic obstructive cardiomyopathy peak rest gradient &gt; 20 mmHg IV contrast NSAID use past 1 week ( uNGAL relate requirement )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Treatment option acute decompensated heart failure</keyword>
	<keyword>Ultrafiltration</keyword>
	<keyword>tolvaptan</keyword>
</DOC>